The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Early Detection of Pompe Disease by Newborn Screening Is Feasible: Results From the Taiwan Screening Program
Abstract
OBJECTIVE. Pompe disease is an autosomal recessive lysosomal storage disorder that is caused by deficient acid α-glucosidase activity and results in progressive, debilitating, and often life-threatening symptoms involving the musculoskeletal, respiratory, and cardiac systems. Recently, enzyme replacement therapy with alglucosidase α has become possible, but the best outcomes in motor function have been achieved when treatment was initiated early. The aim of this study was to test the feasibility of screening newborns in Taiwan for Pompe disease by using a fluorometric enzymatic assay to determine acid α-glucosidase activity in dried blood spots. METHODS. We conducted a large-scale newborn screening pilot program between October 2005 and March 2007. The screening involved measuring acid α-glucosidase activity in dried blood spots of ∼45% of newborns in Taiwan. The unscreened population was monitored as a control. RESULTS. Of the 132 538 newborns screened, 1093 (0.82%) repeat dried blood-spot samples were requested and retested, and 121 (0.091%) newborns were recalled for additional evaluation. Pompe disease was confirmed in 4 newborns. This number was similar to the number of infants who received a diagnosis of Pompe disease in the control group (n = 3); however, newborn screening resulted in an earlier diagnosis of Pompe disease: patients were <1 month old compared with 3 to 6 months old in the control group. CONCLUSIONS. To our knowledge, this is the first large-scale study to show that newborn screening for Pompe disease is feasible. Newborn screening allows for earlier diagnosis of Pompe disease and, thus, for assessment of the value of an earlier start of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olgemöller, B., Roscher, A. A., Liebl, B., & Fingerhut, R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021732 · Cited by 124
Cited by
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants
Kishnani, P. S., Goldenberg, P. C., DeArmey, S. L., Heller, J., Benjamin, D., Young, S., Bali, D., Smith, S. A., Li, J. S., Mandel, H., et al. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.08.003 · Cited by 383
Self-citationDesnick, R. J., & Schuchman, E. H. (2012) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090711-163739 · Cited by 269
Newborn screening for lysosomal storage disorders and other neuronopathic conditions
Matern, D., Oglesbee, D., & Tortorelli, S. (2013) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.1117 · Cited by 41
“However, NBS for Pompe and then Fabry diseases was introduced in screening centers in Taiwan, which together cover approximately 90% of the country’s newborn population [Chien et al., 2008; Hwu et al., 2009; Lin et al., 2009].”
BackgroundMethod
Metadata
- Authors
- Chien, Y.-H., Chiang, S.-C., Zhang, X. K., Keutzer, J., Lee, N.-C., Huang, A.-C., Chen, C.-A., Wu, M.-H., Huang, P.-H., Tsai, F.-J., Chen, Y.-T., & Hwu, W.-L.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2008-07-01
- Volume
- 122
- Issue
- 1
- Pages
- e39-e45
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2102833178
- Cited by
- 242
- References
- 1
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.